Chataway J - Search Results

1

The impact of smoking cessation on multiple sclerosis disease progression.

Rodgers J, Friede T, Vonberg FW, Constantinescu CS, Coles A, Chataway J, Duddy M, Emsley H, Ford H, Fisniku L, Galea I, Harrower T, Hobart J, Huseyin H, Kipps CM, Marta M, McDonnell GV, McLean B, Pearson OR, Rog D, Schmierer K, Sharrack B, Straukiene A, Wilson HC, Ford DV, Middleton RM, Nicholas R. Rodgers J, et al. Among authors: chataway j. Brain. 2022 May 24;145(4):1368-1378. doi: 10.1093/brain/awab385. Brain. 2022. PMID: 34623418 Free PMC article.

2

The genetics of multiple sclerosis: principles, background and updated results of the United Kingdom systematic genome screen.

Chataway J, Feakes R, Coraddu F, Gray J, Deans J, Fraser M, Robertson N, Broadley S, Jones H, Clayton D, Goodfellow P, Sawcer S, Compston A. Chataway J, et al. Brain. 1998 Oct;121 ( Pt 10):1869-87. doi: 10.1093/brain/121.10.1869. Brain. 1998. PMID: 9798743 Review.

3

Multiple sclerosis in sibling pairs: an analysis of 250 families.

Chataway J, Mander A, Robertson N, Sawcer S, Deans J, Fraser M, Broadley S, Clayton D, Compston A. Chataway J, et al. J Neurol Neurosurg Psychiatry. 2001 Dec;71(6):757-61. doi: 10.1136/jnnp.71.6.757. J Neurol Neurosurg Psychiatry. 2001. PMID: 11723196 Free PMC article.

4

Home versus outpatient administration of intravenous steroids for multiple-sclerosis relapses: a randomised controlled trial.

Chataway J, Porter B, Riazi A, Heaney D, Watt H, Hobart J, Thompson A. Chataway J, et al. Lancet Neurol. 2006 Jul;5(7):565-71. doi: 10.1016/S1474-4422(06)70450-1. Lancet Neurol. 2006. PMID: 16781986 Clinical Trial.

5

Grey matter magnetization transfer ratio independently correlates with neurological deficit in secondary progressive multiple sclerosis.

Hayton T, Furby J, Smith KJ, Altmann DR, Brenner R, Chataway J, Hughes RA, Hunter K, Tozer DJ, Miller DH, Kapoor R. Hayton T, et al. Among authors: chataway j. J Neurol. 2009 Mar;256(3):427-35. doi: 10.1007/s00415-009-0110-4. Epub 2009 Mar 6. J Neurol. 2009. PMID: 19271108

6

Multiple sclerosis.

Nicholas R, Chataway J. Nicholas R, et al. Among authors: chataway j. BMJ Clin Evid. 2007 Aug 15;2007:1202. BMJ Clin Evid. 2007. PMID: 19454107 Review.

7

A longitudinal study of MRI-detected atrophy in secondary progressive multiple sclerosis.

Furby J, Hayton T, Altmann D, Brenner R, Chataway J, Smith KJ, Miller DH, Kapoor R. Furby J, et al. Among authors: chataway j. J Neurol. 2010 Sep;257(9):1508-16. doi: 10.1007/s00415-010-5563-y. Epub 2010 May 1. J Neurol. 2010. PMID: 20437181

8

Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial.

Kapoor R, Furby J, Hayton T, Smith KJ, Altmann DR, Brenner R, Chataway J, Hughes RA, Miller DH. Kapoor R, et al. Among authors: chataway j. Lancet Neurol. 2010 Jul;9(7):681-8. doi: 10.1016/S1474-4422(10)70131-9. Epub 2010 Jun 8. Lancet Neurol. 2010. PMID: 20621711 Clinical Trial.

9

A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis.

Chataway J, Nicholas R, Todd S, Miller DH, Parsons N, Valdés-Márquez E, Stallard N, Friede T. Chataway J, et al. Mult Scler. 2011 Jan;17(1):81-8. doi: 10.1177/1352458510382129. Epub 2010 Aug 26. Mult Scler. 2011. PMID: 20798135

10

Designing a seamless phase II/III clinical trial using early outcomes for treatment selection: an application in multiple sclerosis.

Friede T, Parsons N, Stallard N, Todd S, Valdes Marquez E, Chataway J, Nicholas R. Friede T, et al. Among authors: chataway j. Stat Med. 2011 Jun 15;30(13):1528-40. doi: 10.1002/sim.4202. Epub 2011 Feb 22. Stat Med. 2011. PMID: 21341301

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

229 results

Search Page